Preclinical Testing of a Therapeutic Candidate for Usher III in Retinal Organoids Tender

Procurement Summary

Country : USA

Summary : Preclinical Testing of a Therapeutic Candidate for Usher III in Retinal Organoids

Deadline : 07 Jul 2025

Other Information

Notice Type : Tender

TOT Ref.No.: 121971757

Document Ref. No. : 75N95025Q00202

Financier : Self Financed

Purchaser Ownership : Public

Tender Value : Refer Document

Purchaser's Detail

Name :Login to see tender_details

Address : Login to see tender_details

Email : Login to see tender_details

Login to see details

Tender Details

Description

This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement.



This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement, to determine the method of acquisition, and availability of domestic sources manufactured in the United States in sufficient and reasonably available commercial quantities and of a satisfactory quality. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Small businesses are encouraged to respond.



Background: Usher syndrome (USH) is the primary cause of genetic deafness and blindness, with type III being the rarest, comprising just 2-5% of all USH cases. USH3 patients typically have normal hearing and vision at birth, by age 30 to 50, most become legally blind and profoundly deaf. Hearing loss generally occurs before visual decline and while cochlear implants can mitigate deafness, there is currently no treatment or cure for USH3-related vision loss. BF844, a novel small molecule is a potential therapeutic for USH3 patients. BF844 administration attenuated progressive hearing loss and prevented deafness in these models, however, its effect on vision is unknown due to lack of appropriate animal models. Retinal organoids are an alternate approach and have been used to test different therapeutics in various studies (e.g. PMID: 40118996, PMID: 38323188). Retinal organoids with the visual phenotype of USH3 can b...
Active Contract Opportunity
Notice ID : 75N95025Q00202
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : NATIONAL INSTITUTES OF HEALTH
Office: NATIONAL INSTITUTES OF HEALTH NIDA
General Information
Contract Opportunity Type: Sources Sought (Original)
Original Published Date: Jul 02, 2025 08:44 am EDT
Original Response Date: Jul 07, 2025 11:00 am EDT
Inactive Policy: 15 days after response date
Original Inactive Date: Jul 22, 2025
Initiative: None

Classification
Original Set Aside:
Product Service Code: Q301 - REFERENCE LABORATORY TESTING
NAICS Code: 54138 - Testing Laboratories and Services

Place of Performance: USA

Documents

 Tender Notice